BC Innovations | May 14, 2019
Distillery Therapeutics

TRPC6 inhibitor for cardiac and renal fibrosis

DISEASE CATEGORY: Cardiovascular; renal INDICATION: Cardiovascular; renal Cell culture and mouse studies identified a trifluoromethylphenyl-based TRPC6 inhibitor that could help treat cardiac and renal fibrosis. High throughput screening of a small molecule library in cell-based...
BC Innovations | Dec 19, 2018
Distillery Therapeutics

Inflammation

INDICATION: Cytokine release syndrome (CRS) Mouse studies suggest down-regulating catecholamines with NPPA or the TYH inhibitor Demser could help treat CRS. In a mouse model of colon cancer with Clostridium novyi -NT-induced CRS, C. novyi...
BC Extra | Dec 12, 2018
Preclinical News

Repurposing hypertension drugs to block cytokine release syndrome

Johns Hopkins University School of Medicine researchers showed that hypertension drug Demser metyrosine and an endogenous peptide in testing for hypertension could prevent cytokine release syndrome, a toxicity associated with immunotherapies, without compromising efficacy. Cytokine...
BC Innovations | Nov 30, 2016
Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Cell culture and mouse studies suggest inhibiting PDE-1C could help treat heart failure. In two mouse cardiomyocyte-based models of chemical-induced hypertrophy, PDE-1C knockout decreased hypertrophy compared with normal PDE-1C expression, and in...
BioCentury | Nov 16, 2015
Regulation

Scaling compassion

Nearly two years after a viral media campaign saved seven-year-old Josh Hardy's life and put demands for access to unapproved medicines on front pages, drug companies, FDA, academic bioethicists, and patient advocates are beginning to...
BC Week In Review | May 25, 2015
Company News

Antisense Therapeutics, Cortendo deal

Antisense granted Cortendo exclusive rights to develop and commercialize ATL1103 for endocrinology indications. Antisense will receive $5 million up front and is eligible for up to $105 million in development and commercialization milestones, plus royalties....
BC Week In Review | Apr 13, 2015
Clinical News

Antineoplastons: Phase II data

A U.S. Phase II trial in 19 evaluable patients with newly diagnosed anaplastic astrocytoma showed that ANP every 4 hours led to a complete response rate of 21% and a stable disease rate of 26%....
BC Week In Review | Oct 6, 2014
Financial News

Antisense Therapeutics completes private placement

Antisense Therapeutics Ltd. (ASX:ANP), Toorak, Australia   Business: Autoimmune, Endocrine/Metabolic, Cancer   Date completed: 2014-09-25   Type: Private placement   Raised: A$1 million ($872,200)   Shares: 8.7 million   Price: A$0.12   Shares after offering:...
BC Week In Review | Oct 6, 2014
Financial News

Antisense Therapeutics proposes private placement

Antisense Therapeutics Ltd. (ASX:ANP), Toorak, Australia   Business: Autoimmune, Endocrine/Metabolic, Cancer   Date announced: 2014-09-25   Type: Private placement   To be raised: Up to A$1.5 million ($1.3 million)   Shares: 13 million   Price:...
BC Week In Review | Sep 8, 2014
Clinical News

ATL1103: Additional Phase II data

An open-label, European and Australian Phase II trial in 26 acromegalic patients showed that 200 mg ATL1103 given 3 times in week 1 followed by twice-weekly 200 mg ATL1103 for 12 weeks met the primary...
Items per page:
1 - 10 of 536